课题基金 / 基金详情

IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER

IMMUNOLIPOSOME MEDIATED GENE THERAPY FOR PROSTATE CANCER
免疫脂质体介导的前列腺癌基因治疗
批准号:
2777544
负责人:
Esther H Chang
金额:
$13.86万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-03-01 至 2000-02-29

项目摘要

项目成果

Esther H Chang的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自申请人摘要)晚期前列腺癌 倾向于对标准化疗剂相对难治, 化学抗性与功能性p53的缺乏相关。我们的初步数据 表明癌细胞可以通过p53对化疗敏感 使用肿瘤靶向脂质体递送系统进行替代。在这 一个建议,一个重组单链片段(scFv)来源于单克隆抗体, 抗体将用于靶向已知的转铁蛋白受体, 在多种肿瘤类型的细胞表面升高,包括 前列腺在第一阶段,免疫脂质体的脂质组成将是 优化,表达和纯化scFv,并测试递送系统 使用培养的人类前列腺癌细胞。p53基因的影响 恢复这些细胞对各种常用的 将评估化疗剂。最后,使用裸鼠模型, 涉及人前列腺癌异种移植物,免疫脂质体的能力 将测试靶向原发性和转移性前列腺肿瘤。的 该项目的长期目标是开发和营销更 免疫脂质体介导p53基因治疗前列腺癌 治疗加化疗 拟定商业应用:不可用
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that cancer cells can be sensitized to chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In this proposal, a recombinant single-chain fragment (scFv) derived from a monoclonal antibody will be employed to target the transferrin receptor that is known to be elevated on the surface of cells from a variety of tumor types including prostate. In Phase I, the lipid composition of the immunoliposome will be optimized, the scFv expressed and purified, and the delivery system tested using human prostate cancer cells in culture. The impact of p53 gene restoration on the sensitivity of these cells to a variety of commonly used chemotherapeutic agents will be assessed. Finally, using a nude mouse model involving human prostate cancer xenografts, the ability of the immunoliposomes to target primary and metastatic prostate tumors will be tested. The longer-term aim of this project is development and marketing of a more effective treatment for prostate cancer using immunoliposome-mediated p53 gene therapy plus chemotherapy. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment
  • 批准号:
    9409281
  • 项目类别:
  • 资助金额:
    $29.93万
  • 财政年份:
    2017
  • 负责人:
    Esther H Chang
  • 依托单位:
Nanoimmunoliposome-Complexed SPIO: Tumor-Specific Detection of Early Lung Cancer
  • 批准号:
    7363424
  • 项目类别:
  • 资助金额:
    $61.46万
  • 财政年份:
    2008
  • 负责人:
    Esther H Chang
  • 依托单位:
Nanoimmunoliposome-Complexed SPIO: Tumor-Specific Detection of Early Lung Cancer
  • 批准号:
    7546974
  • 项目类别:
  • 资助金额:
    $63.32万
  • 财政年份:
    2008
  • 负责人:
    Esther H Chang
  • 依托单位:
Nanoimmunoliposome-Complexed SPIO: Tumor-Specific Detection of Early Lung Cancer
  • 批准号:
    7750581
  • 项目类别:
  • 资助金额:
    $63.06万
  • 财政年份:
    2008
  • 负责人:
    Esther H Chang
  • 依托单位:
海外基金